Cover Image
市場調查報告書

循環腫瘤細胞 (CTC)、 無細胞DNA、外吐小體/微囊泡癌症細胞診斷:2017-2020年

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

出版商 Howe Sound Research 商品編碼 461737
出版日期 內容資訊 英文 251 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
循環腫瘤細胞 (CTC)、 無細胞DNA、外吐小體/微囊泡癌症細胞診斷:2017-2020年 Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides
出版日期: 2017年03月07日 內容資訊: 英文 251 Pages
簡介

本報告提供全球循環腫瘤細胞 (CTC)、 無細胞DNA、外吐小體/微囊泡癌症細胞診斷市場採納,主要國家及各檢驗領域的規模、費用、收益資料,市場上近幾年趨勢,主要企業簡介,為您概述為以下內容。

第1章 簡介、市場定義

第2章 市場概要

  • 市場參與企業
  • 定序的革命
  • 市場定義
  • 調查手法
  • 液態切片相關支出展望

第3章 市場趨勢

  • 促進成長要素
  • 阻礙成長要素
  • 設備、自動化
  • 診斷技術的開發

第4章 液態切片的近幾年的發展趨勢

第5章 各國的市場規模:北美

  • 美國
    • 肺癌檢驗:規模、費用、收益
    • 乳癌檢驗:規模、費用、收益
    • 大腸癌檢驗:規模、費用、收益
    • 前列腺癌檢驗:規模、費用、收益
    • 其他癌症檢驗:規模、費用、收益
    • 液態切片全體:規模、費用、收益
  • 加拿大

第6章 各國市場:歐洲

  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 其他的歐洲

第7章 各國市場:亞太地區

  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 其他的亞太地區

第8章 各國市場:南美、非洲、中東

  • 巴西
  • 墨西哥
  • 其他南美
  • 非洲、中東

第9章 全球市場的摘要

  • 全球市場

第10章 潛在的市場機會的規模

  • 癌症篩檢:各國 (肺癌、乳癌、大腸癌)
  • 癌症篩檢:各國 (前列腺癌、其他癌症)
  • 潛在的市場機會:癌症診斷
  • 潛在的市場機會:癌症管理

附錄

圖表

目錄

The Diagnostic, Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers . The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase .

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers .

What is the size of the huge screening opportunity ? They are all listed in Chapter 10.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell is a member of The American Association for Clinical Chemistry. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Liquid Biopsy Market - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Liquid Biopsy?
  • 1.2 The Sequincing Revolution
  • 1.3 Market Definition
    • 1.3.1 Volumes
    • 1.3.2 Prices
    • 1.3.3 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Liquid Biopsy
    • 1.5.1 An Historical Look at Clinical Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Genomic Instrumentation Supplier
    • 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4 Pharmaceutical/Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab.
    • 2.1.8 Physician Lab
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Using Biopsies
    • 2.2.1 Cancer
    • 2.2.2 Precancerous conditions
    • 2.2.3 Inflammatory conditions
  • 2.3 Biopsy Sites
  • 2.4 The Situation Today - Biopsy Analysis
    • 2.5 Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1 The Big Picture on Liquid Biopsy Technology
    • 2.5.2 The Role of CTCs
      • 2.5.2.1 Types of CTCs
      • 2.5.2.2 CellSearch Detection- Ultimate Sensitivity
      • 2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
      • 2.5.2.4 Maintrac Detection - The Microscope.
      • 2.5.2.5 Other Methods
    • 2.5.3 ctDNA - Going Mainstream?
    • 2.5.4 Exosomes and Micro Vesicles - New Kid on Block
  • 2.6 Cancer Treatment Protocol Under Siege
    • 2.6.1 Issues and Limitations to Liquid Biopsy Adoption
    • 2.6.2 The Cancer Screening Market Opportunity
      • 2.6.2.1 GRAIL - What Is It?
    • 2.6.3 Cancer Management vs. Diagnosis
      • 2.6.3.1 The Role of Risk Assessment
      • 2.6.3.2 Managing Therapy
      • 2.6.3.3 Monitoring Disease - What Is It?
    • 2.6.4 Phases of Adoption - Looking Into The Future
    • 2.6.5 The Promise of Liquid Biopsy
  • 2.7 Structure of Industry Plays a Part
    • 2.7.1 Hospital Testing Share
    • 2.7.2 Economies of Scale
    • 2.7.2.1 Hospital vs. Central Lab
    • 2.7.3 Physician Office Lab's
    • 2.7.4 Physician's and POCT.
  • 2.8 Profiles of Key Players
    • 2.8.1 AdnaGen (now Qiagen)
    • 2.8.2 Agena Bioscience
    • 2.8.3 Angle plc
    • 2.8.4 ApoCell
    • 2.8.5 Biocept
    • 2.8.6 BioFluidica
    • 2.8.7 Bio-Rad Laboratories
    • 2.8.8 Boreal Genomics
    • 2.8.10 Chronix Biomedical
    • 2.8.11 Clearbridge BioMedics
    • 2.8.12 Cynvenio
    • 2.8.13 Cytolumina Technologies Corp
    • 2.8.14 CytoTrack
    • 2.8.15 Diagnologix LLC
    • 2.8.16 Epic Sciences
    • 2.8.17 Exosome Diagnostics
    • 2.8.18 Exosome Sciences
    • 2.8.19 Fluidigm Corp
    • 2.8.20 Fluxion Biosciences
    • 2.8.21 Genomic Health
    • 2.8.39 GRAIL
    • 2.8.22 Guardant Health
    • 2.8.23 HansaBiomed
    • 2.8.23 Horizon Discovery
    • 2.8.24 iCellate
    • 2.8.25 Illumina
    • 2.8.26 Inivata
    • 2.8.27 Janssen Diagnostics
    • 2.8.28 Molecular MD
    • 2.8.29 Myriad Genetics
    • 2.8.30 Natera
    • 2.8.31 New Oncology
    • 2.8.32 Personal Genome Diagnostics
    • 2.8.33 RainDance Technologies
    • 2.8.34 Rarecells SAS
    • 2.8.35 Silicon Biosystems
    • 2.8.36 Sysmex Inostics
    • 2.8.37 SRI International
    • 2.8.38 Trovagene

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Non Invasive Game Changer
    • 3.1.2 Lower Cost
    • 3.1.3 Greater Accuracy.
    • 3.1.4 Wide Range of Potential Uses
    • 3.1.5 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 Lower prices
    • 3.2.2 Lack of Standards.
    • 3.2.3 Protocol Resistance.
    • 3.2.4 Initial Adoption Has No Cost Savings
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role.
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World.
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
  • 4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy
  • 4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy
  • 4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study
  • 4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen
  • 4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test
  • 4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options
  • 4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab
  • 4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance
  • 4.10 Biocept Q1 Revenues Rise With Test Volume Growth
  • 4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers
  • 4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood
  • 4.13 Cynvenio to present new clinical data
  • 4.14 EKF, Angle Collaborate for Liquid Biopsy Development
  • 4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer
  • 4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen
  • 4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics
  • 4.18 Merck Serono and Sysmex Inostics Announce Testing Center
  • 4.19 Agena Bioscience Launches Smaller Format MassArray
  • 4.20 Personal Genome Diagnostics Aims for FDA Clearance
  • 4.21 HTG Molecular Diagnostics Files for IPO of up to $60M
  • 4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter
  • 4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs
  • 4.24 Inivata Raises $6.6M to Develop ctDNA Assays
  • 4.25 Epic Sciences Raises $30M in Private Financing
  • 4.26 New Release in Line of Liquid Biopsy CLIA Tests
  • 4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test
  • 4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field
  • 4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test
  • 4.29 DNA in blood can track cancer development, response in real time
  • 4.30 Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing
  • 4.31 Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay
  • 4.32 Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System
  • 4.33 MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States
  • 4.34 GATC Biotech's Liquid Biopsy Testing Takes Cost Lead
  • 4.35 Liquid Biotech USA, Inc. Announces Completion of Clinical Study
  • 4.36 Liquid biopsies more effective in some cases than tissue biopsies
  • 4.37 Cancer Genetics, Inc. and ApoCell Announce Partnership for Rare Cell Capture and Detection
  • 4.38 Exosome Diagnostics Launches Liquid Biopsy Test to Rule Out High-Grade Prostate Cancer
  • 4.39 Liquid Biopsy Tests Partially Validated
  • 4.40 FDA Approves Liquid Biopsy
  • 4.41 Liquid Biopsy Predicts Colon Cancer Recurrence
  • 4.42 WaveSense Receives CE-IVD Mark for Cell Enrichment Platform
  • 4.43 For Liquid Biopsy, Size Matters
  • 4.44 Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz
  • 4.45 Trovagene, USC Collaborate on Deployment of Urine-Based Liquid Biopsy Test
  • 4.46 Circulogene liquid biopsy detects new tumor mass earlier than current imaging methods
  • 4.47 Clinical Utility of Biocept's Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium
  • 4.48 Trovagene to Focus More on Liquid Biopsy Testing Market
  • 4.49 Pancreatic Cancer Gets Prognostic Tool from Liquid Biopsy
  • 4.50 New Start-up to Work on Scalpel-free "Liquid Biopsies"
  • A researher at University of California, Berkeley, is launching a start-up called KarnaTeq to develop and market technology to increase the diagnostic power of scalpel-free biopsy.

5. Country Market Sizes - North America

  • 5.1 United States of America
    • 5.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 5.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 5.2 Canada
    • 5.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 5.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1 France
    • 6.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.2 Germany
    • 6.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.3 United Kingdom
    • 6.3.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.3.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.3.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.4 Spain
    • 6.4.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.4.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.4.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.5 Italy
    • 6.5.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.5.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.5.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.5.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.5.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.5.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.6 Russia
    • 6.6.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.6.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.6.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.6.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.6.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.6.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.7 Remainder of Europe and Former Soviet Union
    • 6.7.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.7.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.7.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.7.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.7.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 6.7.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1 China
    • 7.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.2 Japan
    • 7.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.3 South Korea
    • 7.3.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.3.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.3.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.4 India
    • 7.4.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.4.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.4.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.5 Australia
    • 7.5.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.5.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.5.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.5.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.5.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.5.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.6 Rest of Asia Pacific
    • 7.6.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.6.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.6.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.6.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.6.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 7.6.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1 Brazil
    • 8.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.2 Mexico
    • 8.2.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.2.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.2.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.2.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.2.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.2.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.3 Rest of Latin America
    • 8.3.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.3.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.3.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.3.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.3.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.3.6 All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.4 Africa and The Middle East
    • 8.4.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.4.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.4.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.4.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.4.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 8.4.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1 Global
    • 9.1.1 Lung Cancer Testing - Volumes, Prices, Revenues
    • 9.1.2 Breast Cancer Testing - Volumes, Prices, Revenues
    • 9.1.3 Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 9.1.4 Prostate Cancer Testing - Volumes, Prices, Revenues
    • 9.1.5 Other Cancer Testing - Volumes, Prices, Revenues
    • 9.1.6 All Liquid Biopsy Total - Volumes, Prices, Revenues

10. Potential Market Opportunity Sizes

  • 10.1 Cancer Screening by Country: Lung, Breast & Colorectal
  • 10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 10.3 Potential Market Size - Cancer Diagnosis
  • 10.4 Potential Market Size - Cancer Management

Appendices

  • I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2 Market Players by Type
  • Table 3 Biopsy Sites
  • Table 4 Advantages of Liquid Biopsy in Screening Market
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends.
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 10 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 11 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 12 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 13 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 14 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 15 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 16 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 17 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 18 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 19 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 20 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 21 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 22 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 23 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 24 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 25 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 26 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 27 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 28 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 29 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 30 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 31 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 32 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 33 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 34 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 35 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 36 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 37 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 38 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 39 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 40 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 41 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 42 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 43 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 44 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 45 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 46 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 47 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 48 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 49 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 50 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 51 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 52 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 53 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 54 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 55 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 56 All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 57 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 58 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 59 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 60 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 61 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 62 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 63 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 64 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 65 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 66 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 67 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 68 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 69 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 70 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 71 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 72 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 73 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 74 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 75 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 76 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 77 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 78 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 79 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 80 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 81 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 82 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 83 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 84 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 85 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 86 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 87 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 88 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 89 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 90 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 91 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 92 All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 93 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 94 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 95 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 96 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 97 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 98 All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 99 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 100 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 101 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 102 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 103 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 104 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 105 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 106 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 107 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 108 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 109 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 110 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 111 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 112 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 113 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 114 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 115 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 116 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 117 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 118 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 119 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 120 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 121 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 122 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 123 Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 124 Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 125 Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 126 Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 127 Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 128 All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 129 Potential Screening Market: Lung, Breast & Colorectal
  • Table 130 Potential Screening Market: Prostate, Other & All
  • Table 131 Potential Cancer Diagnosis Market Size
  • Table 132 Potential Cancer Management Market Size
  • Table 133 2015 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2 Comparison of Liquid Biopsy Classes
  • Figure 3 Characteristics of Different Vesicle Types
  • Figure 4 Percentage of World Population Over 65
Back to Top